Loading organizations...

iRhythm Technologies is a technology company.
iRhythm Technologies develops and commercializes the Zio system, an innovative, discreet, and wearable adhesive patch designed for continuous ambulatory cardiac rhythm monitoring. This end-to-end service captures and analyzes heartbeat data over extended periods, utilizing advanced proprietary algorithms and artificial intelligence to identify and diagnose various cardiac arrhythmias, delivering comprehensive reports to healthcare providers. The technology aims to provide a more accurate and patient-friendly diagnostic solution compared to traditional methods.
The company was founded by electrophysiologist Dr. Uday Kumar, and incorporated in Delaware on September 14, 2006. Dr. Kumar's foundational insight stemmed from recognizing a critical unmet need for a more efficient and comfortable method of long-term cardiac monitoring, as existing solutions often failed to adequately capture intermittent arrhythmias or were burdensome for patients. His vision was to create a simplified, high-fidelity diagnostic tool.
The Zio system primarily serves clinicians who require precise and timely diagnostic information for their patients experiencing potential cardiac rhythm disorders, while also offering a comfortable and convenient experience for patients. iRhythm's long-term vision is to transform cardiac care by providing accessible, precise, and insightful diagnostic information, thereby enabling earlier and more effective management of heart conditions and ultimately improving patient health outcomes globally.
iRhythm Technologies has raised $112.0M across 8 funding rounds.
iRhythm Technologies has raised $112.0M in total across 8 funding rounds.
iRhythm Technologies is a leading digital healthcare company specializing in cardiac monitoring solutions, primarily through its Zio® ECG monitors and end-to-end monitoring services.[1][2][3][6] It builds wearable, patient-friendly devices like the Zio monitor for long-term continuous monitoring (LTCM) and Zio AT® for mobile cardiac telemetry (MCT), combined with FDA-cleared deep-learned AI algorithms and Qualified Cardiac Technicians (QCTs) for analysis, serving healthcare professionals, cardiologists, electrophysiologists, and risk-based organizations to detect arrhythmias such as atrial fibrillation.[1][3][4][5] These solutions solve the problem of inaccurate, low-compliance cardiac monitoring by delivering 99% patient compliance, clinical accuracy matching cardiologists, and succinct reports with 99% physician agreement, having processed over 10 million patient reports and 2 billion hours of heartbeat data to enable timely diagnoses, reduce care costs, and support value-based care.[2][3][4][5]
The company's growth momentum is strong, evidenced by international expansion including a 2025 launch of Zio LTCM services in Japan with PMDA approval, seamless EHR integration for efficiency, and over 100 scientific studies validating its precision.[3][5][6][7]
Search results do not provide specific details on iRhythm Technologies' founding year, founders, or early backstory, focusing instead on current products and services.[1-9] The company has evolved into a digital health leader combining wearable ECG technology with AI-driven analysis, as demonstrated by its development of the Zio platform from earlier generations like Zio XT to advanced monitors with deep-learned algorithms cleared by FDA, CE mark, UKCA, and PMDA.[1][3][4][5][6] Pivotal moments include achieving near-perfect patient compliance and clinician agreement, processing billions of hours of data, and recent expansions like Japan market entry in 2025.[2][3][6]
iRhythm stands out in cardiac monitoring through these key strengths:
iRhythm rides the wave of AI-powered digital health and wearable diagnostics, addressing rising cardiovascular disease prevalence amid shifts to value-based care and remote monitoring post-pandemic.[2][3][6] Timing is ideal as aging populations and arrhythmia detection needs grow, with market forces like EHR adoption and regulatory approvals (FDA, CE, PMDA) favoring scalable, compliant solutions over traditional monitors.[1][4][5][7] It influences the ecosystem by setting benchmarks for precision (e.g., cardiologist-level AI), improving outcomes like faster atrial fibrillation diagnoses, and enabling risk-based organizations to prevent disease while cutting costs—processing 2 billion heartbeat hours demonstrates its scale in transforming fragmented cardiac care.[2][3][5]
iRhythm is poised for continued expansion with its AI-human hybrid model, likely deepening global penetration (e.g., post-Japan launch) and integrating into more EHRs for streamlined workflows.[3][6][7] Trends like advancing AI for predictive analytics, broader arrhythmia detection, and telehealth will shape its path, potentially evolving from monitoring to full disease prediction/prevention platforms.[2][5][6] As cardiac tech consolidates around high-compliance wearables, iRhythm's precision edge positions it to dominate, building on its mission to transform monitoring with every heartbeat.[1][3]
iRhythm Technologies has raised $112.0M in total across 8 funding rounds.
iRhythm Technologies's investors include Tiba Aynechi, Norwest Venture Partners, Casper de Clercq, Kaiser Permanente Ventures, New Leaf Ventures, Synergy Life Science Partners, New Leaf Venture Partners, St. Jude Medical, Mohr Davidow Ventures, Stanford University, UNC Kenan-Flagler.
iRhythm Technologies has raised $112.0M across 8 funding rounds. Most recently, it raised $27.0M Series E in May 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2014 | $27.0M Series E | Tiba Aynechi | Norwest Venture Partners, Norwest Venture Partners |
| Apr 1, 2013 | $16.0M Series D | Casper de Clercq | Norwest Venture Partners, Kaiser Permanente Ventures, New Leaf Ventures, Synergy Life Science Partners |
| May 13, 2011 | $15.0M Other Equity | New Leaf Venture Partners | St. Jude Medical |
| May 1, 2011 | $15.0M Series C | Mohr Davidow Ventures, Norwest Venture Partners | |
| May 18, 2010 | $10.0M Other Equity | St. Jude Medical | Mohr Davidow Ventures, Synergy Life Science Partners |
| May 1, 2010 | $10.0M Venture Round | Mohr Davidow Ventures, Norwest Venture Partners | |
| May 1, 2009 | $7.0M Series B | Mohr Davidow Ventures, Norwest Venture Partners, Stanford University, Synergy Life Science Partners, UNC Kenan-Flagler | |
| Feb 1, 2007 | $12.0M Series A | Mohr Davidow Ventures, Synergy Life Science Partners | Norwest Venture Partners |